By Connor Hart
Shares of Claritev fell after the healthcare technology company said certain affiliates of Hellman & Friedman will sell 1.5 million shares of its common stock to the public at $51.50 apiece.
The stock slid 9.6% to $53.43 in premarket trading Thursday. Through Wednesday's close, shares had nearly quadrupled so far this year.
The McLean, Va.-based company said late Wednesday that the selling shareholders will also grant underwriters a 30-day option to purchase up to an additional 225,000 shares.
Claritev won't sell any shares in the offering or receive any proceeds. The offering is expected to close by Friday.
Barclays, Guggenheim Securities and Wells Fargo Securities are acting as joint lead bookrunners for the deal, with Citigroup and Piper Sandler serving as additional bookrunners.
Write to Connor Hart at connor.hart@wsj.com
(END) Dow Jones Newswires
November 13, 2025 08:36 ET (13:36 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.